JBS on NYSE
JBS N.V.
Meat packing plants company, listed on NYSE (JBS). Summary from the record
$13.05 up 0.33 (2.59%)Price as of Oct 16, 2026 at 19:58 UTC
Last updated Oct 19, 2026.
Overview
Compare with JBS S.A., Smithfield Foods or Hormel, or pick any stock.
- TickerJBS on NYSE1
- IndustryMeat Packing Plants1
- HeadquartersP71
- Incorporated inNetherlands4
- Business addressStroombaan 16, 5E Verdieping, Amstelveen4
- Filer categoryLarge accelerated filer4
See how the biggest companies compare on our leaderboards
“Happy Eggs” brand focuses on free-range chickens and “Fazenda da Toca” operates in the organic eggs segment.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
13.1%Gross margin3
4.8%Operating margin3
2.6%Net margin3
11.7%Revenue growth, 20253
23.4%Return on equity3
2.13×Debt to equity3
$832.7MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
Reportable segments [member] brought in 50% of the revenue JBS N.V. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Reportable segments [member] | $74.9B | $78.8B | $88.4B |
| Beef North America | $23.3B | $24.3B | $28.1B |
| Pilgrims Pride | $17.3B | $17.9B | $18.5B |
| BRMember | $11.1B | $12.6B | $15.3B |
| Seara | $8.3B | $8.8B | $9.2B |
| USAPork | $7.7B | $8.1B | $8.4B |
| AUMember | $6.2B | $6.6B | $8.1B |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue87¢$74.9B
- Other costs8¢$7.0B
- Interest2¢$1.7B
- Income tax0¢$390.5M
- Profit3¢$2.2B
Out of $86.2B in revenue.3
Where each dollar of operating cash went, fiscal 2025
- Capital spending57¢$2.1B
- Dividends paid43¢$1.6B
Out of $2.9B of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.3
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| NET REVENUE | $86.2B | $77.2B | $72.9B |
| Cost of sales | -$74.9B | -$65.6B | -$65.0B |
| GROSS PROFIT | $11.3B | $11.6B | $8.0B |
| Selling expenses | -$5.0B | -$4.8B | -$4.6B |
| General and administrative expenses | -$2.2B | -$2.3B | -$2.3B |
| Other income | $111.9M | $84.5M | $148.6M |
| Other expenses | -$75.5M | -$189.3M | -$122.2M |
| NET OPERATING EXPENSES | -$7.1B | -$7.2B | -$6.9B |
| OPERATING PROFIT | $4.2B | $4.4B | $1.1B |
| Finance income | $565.2M | $719.4M | $584.2M |
| Finance expense | -$2.1B | -$2.4B | -$1.9B |
| NET FINANCE EXPENSE | -$1.6B | -$1.7B | -$1.4B |
| Share of profit of equity-accounted investees, net of tax | $16.9M | $2.9M | $9.5M |
| PROFIT (LOSS) BEFORE TAXES | $2.6B | $2.7B | -$259.7M |
| Current income taxes | -$450.2M | -$870.5M | -$69.5M |
| Deferred income taxes | $59.7M | $127.1M | $197.5M |
| TOTAL INCOME TAXES | -$390.5M | -$743.4M | $128.0M |
| Company shareholders | $2.0B | $1.8B | -$198.9M |
| Non-controlling interest | $205.5M | $200.7M | $67.1M |
| NET INCOME (LOSS) | $2.2B | $2.0B | -$131.7M |
| Basic earnings (loss) per share - common shares (US$) (in Dollars per share) | $1.89 | $1.65 | -$0.19 |
| Diluted earnings (loss) per share - common shares (US$) (in Dollars per share) | $1.89 | $1.65 | -$0.19 |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2025-05-31 | 2025-04-30 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $4.6B | $5.6B | $4.6B | ||
| Margin cash | $159.6M | $136.6M | |||
| Trade accounts receivable | $4.2B | $3.7B | |||
| Dividends receivable | $1.5M | ||||
| Inventories | $6.1B | $5.0B | |||
| Biological assets | $1.8B | $1.6B | $1.7B | ||
| Recoverable taxes | $957.2M | $637.7M | |||
| Derivative assets | $155.6M | $84.5M | |||
| Other current assets | $433.4M | $288.8M | |||
| TOTAL CURRENT ASSETS | $18.4B | $17.1B | |||
| Long-term investments | $45.8M | ||||
| Recoverable taxes | $1.9B | $1.4B | |||
| Biological assets | $611.8M | $518.2M | $531.5M | ||
| Related party receivables | $41.2M | $77.4M | |||
| Deferred income taxes | $547.0M | $651.2M | |||
| Other non-current assets | $488.8M | $268.7M | |||
| TOTAL OTHER NON-CURRENT ASSETS | $3.6B | $2.9B | |||
| Investments in equity-accounted investees | $171.6M | $38.3M | $56.6M | ||
| Property, plant and equipment | $13.6B | $11.8B | $12.9B | ||
| Right of use assets | $1.6B | $1.6B | $1.7B | ||
| Intangible assets | $1.8B | $1.8B | $2.0B | ||
| Goodwill | $5.9B | $5.4B | |||
| TOTAL NON-CURRENT ASSETS | $26.7B | $23.6B | |||
| TOTAL ASSETS | $45.2B | $40.7B | |||
| Trade accounts payable | $6.2B | $5.5B | |||
| Supply chain finance | $1.1B | $728.7M | |||
| Loans and financing | $833.1M | $2.1B | |||
| Income taxes | $288.0M | $233.0M | |||
| Other taxes payable | $153.0M | $113.7M | |||
| Payroll and social charges | $1.6B | $1.4B | |||
| Lease liabilities | $354.9M | $335.7M | |||
| Dividends payable | $1.5B | $358.6M | |||
| Provisions for legal proceedings | $159.2M | $280.8M | |||
| Derivative liabilities | $156.4M | $166.0M | |||
| Other current liabilities | $704.5M | $455.0M | |||
| TOTAL CURRENT LIABILITIES | $11.5B | $11.7B | |||
| Loans and financing | $20.3B | $17.2B | |||
| Income and other taxes payable | $407.7M | $406.7M | |||
| Payroll and social charges | $288.1M | $352.7M | |||
| Lease liabilities | $1.4B | $1.4B | |||
| Deferred income taxes | $1.2B | $1.1B | |||
| Provisions for legal proceedings | $209.4M | $216.7M | |||
| Related party payable | $191.0M | ||||
| Derivative liabilities | $114.4M | $100.1M | |||
| Other non-current liabilities | $42.2M | $81.6M | |||
| TOTAL NON-CURRENT LIABILITIES | $24.1B | $20.9B | |||
| Share capital - common shares | $35.1M | $13.2B | |||
| Reserves | $6.6B | -$6.1B | |||
| Undistributed results | $2.1B | ||||
| Attributable to company shareholders | $8.7B | $7.1B | |||
| Attributable to non-controlling interest | $819.2M | $1.0B | |||
| TOTAL EQUITY | $9.5B | -$5.4B | $8.1B | $9.7B | |
| TOTAL LIABILITIES AND EQUITY | $45.2B | $40.7B |
| Period ending | 2025-12-31 | 2025-05-31 | 2025-04-30 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | $4.6B | $5.6B | $4.6B | $2.5B | ||
| Margin cash | $159.6M | $136.6M | ||||
| Trade accounts receivable | $4.2B | $3.7B | ||||
| Dividends receivable | $1.5M | |||||
| Inventories | $6.1B | $5.0B | ||||
| Biological assets | $1.8B | $1.6B | $1.7B | $1.9B | ||
| Recoverable taxes | $957.2M | $637.7M | ||||
| Derivative assets | $155.6M | $84.5M | ||||
| Other current assets | $433.4M | $288.8M | ||||
| TOTAL CURRENT ASSETS | $18.4B | $17.1B | ||||
| Long-term investments | $45.8M | |||||
| Recoverable taxes | $1.9B | $1.4B | ||||
| Biological assets | $611.8M | $518.2M | $531.5M | $502.0M | ||
| Related party receivables | $41.2M | $77.4M | ||||
| Deferred income taxes | $547.0M | $651.2M | ||||
| Other non-current assets | $488.8M | $268.7M | ||||
| TOTAL OTHER NON-CURRENT ASSETS | $3.6B | $2.9B | ||||
| Investments in equity-accounted investees | $171.6M | $38.3M | $56.6M | $56.5M | ||
| Property, plant and equipment | $13.6B | $11.8B | $12.9B | $11.9B | ||
| Right of use assets | $1.6B | $1.6B | $1.7B | $1.6B | ||
| Intangible assets | $1.8B | $1.8B | $2.0B | $2.0B | ||
| Goodwill | $5.9B | $5.4B | ||||
| TOTAL NON-CURRENT ASSETS | $26.7B | $23.6B | ||||
| TOTAL ASSETS | $45.2B | $40.7B | ||||
| Trade accounts payable | $6.2B | $5.5B | ||||
| Supply chain finance | $1.1B | $728.7M | ||||
| Loans and financing | $833.1M | $2.1B | ||||
| Income taxes | $288.0M | $233.0M | ||||
| Other taxes payable | $153.0M | $113.7M | ||||
| Payroll and social charges | $1.6B | $1.4B | ||||
| Lease liabilities | $354.9M | $335.7M | ||||
| Dividends payable | $1.5B | $358.6M | ||||
| Provisions for legal proceedings | $159.2M | $280.8M | ||||
| Derivative liabilities | $156.4M | $166.0M | ||||
| Other current liabilities | $704.5M | $455.0M | ||||
| TOTAL CURRENT LIABILITIES | $11.5B | $11.7B | ||||
| Loans and financing | $20.3B | $17.2B | ||||
| Income and other taxes payable | $407.7M | $406.7M | ||||
| Payroll and social charges | $288.1M | $352.7M | ||||
| Lease liabilities | $1.4B | $1.4B | ||||
| Deferred income taxes | $1.2B | $1.1B | ||||
| Provisions for legal proceedings | $209.4M | $216.7M | ||||
| Related party payable | $191.0M | |||||
| Derivative liabilities | $114.4M | $100.1M | ||||
| Other non-current liabilities | $42.2M | $81.6M | ||||
| TOTAL NON-CURRENT LIABILITIES | $24.1B | $20.9B | ||||
| Share capital - common shares | $35.1M | $13.2B | ||||
| Reserves | $6.6B | -$6.1B | ||||
| Undistributed results | $2.1B | |||||
| Attributable to company shareholders | $8.7B | $7.1B | ||||
| Attributable to non-controlling interest | $819.2M | $1.0B | ||||
| TOTAL EQUITY | $9.5B | -$5.4B | $8.1B | $9.7B | $9.5B | |
| TOTAL LIABILITIES AND EQUITY | $45.2B | $40.7B |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| NET INCOME (LOSS) | $2.2B | $2.0B | -$131.7M |
| Depreciation and amortization | $2.3B | $2.2B | $2.1B |
| Expected credit losses | $31.7M | $12.9M | $9.9M |
| Share of profit of equity-accounted investees | -$16.9M | -$2.9M | -$9.5M |
| Gain on sales of assets | -$19.6M | -$8.9M | -$14.0M |
| Tax expense | $390.5M | $743.4M | -$128.0M |
| Net finance expense | $1.6B | $1.7B | $1.4B |
| Share-based compensation | $28.9M | $15.8M | $6.9M |
| Provisions for legal proceedings | $189.4M | $47.2M | $106.1M |
| Impairment of goodwill and property, plant and equipment | $12.8M | $28.3M | $30.2M |
| Net realizable value inventory adjustments | $18.2M | $14.0M | -$6.1M |
| DOJ (Department of Justice) and antitrust agreements | $182.3M | $253.7M | $102.5M |
| Fair value adjustment of biological assets | -$19.1M | -$158.6M | $85.0M |
| Extemporaneous Litigation | $20.7M | $61.0M | |
| Extemporaneous Reversal of Tax Credits | $58.7M | ||
| Provision for avian influenza related costs | $17.1M | ||
| Total Adjustments | $6.9B | $6.9B | $3.6B |
| Trade accounts receivable | -$347.3M | -$333.6M | $624.8M |
| Inventories | -$793.7M | -$377.4M | $480.5M |
| Recoverable taxes | $54.0M | $45.4M | $137.7M |
| Other current and non-current assets | -$123.6M | -$7.6M | -$40.9M |
| Biological assets | -$820.6M | -$520.5M | -$529.4M |
| Trade accounts payable and supply chain finance | $612.6M | $344.5M | -$787.0M |
| Taxes paid in installments | -$55.7M | -$61.0M | -$48.1M |
| Other current and non-current liabilities | -$198.6M | $62.4M | $249.5M |
| DOJ and Antitrust agreements payment | -$402.8M | -$170.6M | -$90.3M |
| Income taxes paid | -$809.0M | -$348.7M | -$70.9M |
| Changes in operating assets and liabilities | -$2.9B | -$1.4B | -$74.2M |
| Cash provided by operating activities | $4.0B | $5.5B | $3.5B |
| Interest paid | -$1.3B | -$1.5B | -$1.3B |
| Interest received | $188.4M | $192.2M | $187.4M |
| Net cash flows provided by operating activities | $2.9B | $4.2B | $2.4B |
| Purchases of property, plant and equipment | -$2.1B | -$1.5B | -$1.5B |
| Purchases and disposals of intangible assets | -$7.1M | -$10.6M | -$9.0M |
| Proceeds from sale of property, plant and equipment | $73.2M | $47.2M | $72.0M |
| Additional/Acquistion investments in equity-accounted investees | -$185.7M | ||
| Acquisitions, net of cash acquired | -$5.8M | -$3.5M | |
| Dividends received | $7.3M | $10.7M | $12.6M |
| Related party transactions | -$53.9M | $21.2M | $1.0M |
| Others | -$45.8M | $20.6M | |
| Cash used in investing activities | -$2.3B | -$1.4B | -$1.4B |
| Proceeds from loans and financing | $10.1B | $3.0B | $9.0B |
| Payments of loans and financing | -$8.8B | -$3.0B | -$7.1B |
| Derivative instruments received (settled) | -$86.8M | -$232.0M | -$12.7M |
| Margin cash | -$16.6M | $20.1M | -$26.6M |
| Dividends paid / Share premium distribution | -$1.6B | -$759.3M | -$448.0M |
| Dividends paid to non-controlling interest | -$356.2M | -$4.3M | -$5.9M |
| Purchase of Diamond Pork treasury shares | -$7.6M | ||
| Purchase of treasury shares | -$600.0M | ||
| Payments of leasing contracts | -$432.5M | -$417.8M | -$428.7M |
| Acquisition of non-controlling interests in the subsidiary PPC | -$1.3M | ||
| Others | -$39.3M | ||
| Cash provided by (used in) financing activities | -$1.8B | -$1.4B | $1.0B |
| Effect of exchange rate changes on cash and cash equivalents | $102.8M | -$352.9M | $50.6M |
| Net change in cash and cash equivalents | -$1.0B | $1.0B | $2.0B |
| Non-cash additions to right of use assets and lease liabilities | $404.1M | $505.0M | $483.7M |
| Capitalized interest | $35.0M | $31.7M | $68.2M |
| Dividends Prescribed and payable | $46.0K | $5.0K | $696.0K |
| Interim dividends | $379.6M | ||
| Non-Cash additions to PP&E | $12.5M | ||
| Dividend distribution through liquidation of subsidiaries | -$133.1M |
No quarter-by-quarter statement was filed.
Leadership
Who has led JBS N.V., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
- Chief executive officerGilberto Tomazoni Mar 18, 2026 to now6
- Chief financial officerGuilherme Perboyre Cavalcanti Mar 18, 2026 to now7
Board members and other officers (9)
- Board memberAraujo Carlos Hamilton Vasconcelos Mar 18, 2026 to now8
- Board memberGilberto Tomazoni Mar 18, 2026 to now6
- Board memberHenrique C. Meirelles Mar 18, 2026 to now9
- Board memberJeremiah Alphonsus O'Callaghan Mar 18, 2026 to now10
- Board memberJoesley Mendonca Batista Mar 18, 2026 to now11
- Board memberKatia Regina De Abreu Gomes Mar 18, 2026 to now12
- Board memberPaulo Bernardo Silva Mar 18, 2026 to now13
- Board memberRaul Padilla Mar 18, 2026 to now14
- Board memberWesley Mendonca Batista Mar 18, 2026 to now15
Former names
- JBS B.V.Nov 23, 2022 to May 23, 20254
Timeline
- Mar 18, 2026New chief executive Gilberto Tomazoni becomes CEO6
Filings
144 filings to the SEC since October 2021: 1 annual reports, 1 quarterly reports, 3 major events, 15 insider forms, 5 large holders, 119 other. The latest 20:
- Sep 15, 20268-K CURRENT REPORT EDGAR
- Aug 25, 20264 EDGAR
- Aug 21, 2026144 EDGAR
- Aug 19, 2026425 CURRENT REPORT EDGAR
- Aug 19, 20268-K CURRENT REPORT EDGAR
- Aug 12, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 2026SCHEDULE 13G EDGAR
- Aug 11, 20268-K CURRENT REPORT EDGAR
- Aug 10, 202610-Q EDGAR
- Aug 7, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 31, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 10, 20264 EDGAR
- May 22, 20264 EDGAR
- May 22, 20264 EDGAR
- May 14, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 12, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 12, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Apr 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
The 144 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 24, 2026 | Cavalcanti Guilherme PerboyreGlobal CFO and IRO | Sale | 183,501 | $13.85 | $2.5M | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Capital Research Global InvestorsSCHEDULE 13G/A, 2 filings Nov 13, 2025 to Aug 12, 202616
- DAVIS SELECTED ADVISERSSCHEDULE 13G, 1 filing Aug 12, 202617
- Participacoes S.a. BndesSCHEDULE 13G, 1 filing Aug 14, 202518
- S.a. J&fSCHEDULE 13G, 1 filing Aug 14, 202519
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARJBS N.V. filings on SEC EDGAR
- 2Yahoo FinanceJBS quote
- 3SEC EDGARJBS N.V. 10-K for fiscal 2025
- 4SEC EDGARJBS N.V. filings on SEC EDGAR
- 5
- 6
- 7
- 8
- 9SEC EDGARHenrique C. Meirelles, Board member
- 10
- 11
- 12
- 13SEC EDGARPaulo Bernardo Silva, Board member
- 14SEC EDGARRaul Padilla, Board member
- 15
- 16
- 17
- 18
- 19SEC EDGARS.a. J&f SCHEDULE 13G on JBS N.V.